FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAligos Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALGS
Aligos Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for Aligos Therapeutics, Inc. (ALGS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisALGS
ALGS
Aligos Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
ALGS
  1. Home
  2. Stocks
  3. Aligos Therapeutics, Inc.

Aligos Therapeutics, Inc.

🇺🇸ALGS•NASDAQ

Aligos Therapeutics, Inc.

🇺🇸ALGS•NASDAQ
Market cap
$7.62M

Your view on ALGS

Mkt Cap
$7.62M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Aligos Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Lawrence M. Blatt MBA,
Headquarters
One Corporate Drive, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Lawrence M. Blatt MBA,
Headquarters
One Corporate Drive, South San Francisco, CA, US
Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases.

Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB.

The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH).

In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells.

It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH.

The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Aligos Therapeutics, Inc.. Starting points for Aligos Therapeutics, Inc.: EPS -$6.34, beta 2.42 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Aligos Therapeutics, Inc.. Trailing twelve-month EPS for Aligos Therapeutics, Inc. stands at -$6.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Aligos Therapeutics, Inc.. Aligos Therapeutics, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold ALGS12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
CYTKCytokinetics, IncorporatedHealthcareNASDAQ$7.1B
BXRXQBaudax Bio, Inc.HealthcareOTC$436
BYSIBeyondSpring Inc.HealthcareNASDAQ$13.7M
CABACabaletta Bio, Inc.HealthcareNASDAQ$201.9M
CADLCandel Therapeutics, Inc.HealthcareNASDAQ$395.4M
CAICaris Life Sciences, Inc.HealthcareNASDAQ$5.0B
CAIHFChia Tai Enterprises International LimitedHealthcareOTC$217.4M
CALACalithera Biosciences, Inc.HealthcareOTC$974
CALCCalciMedica, Inc.HealthcareNASDAQ$4.0M
CAMPCAMP4 Therapeutics CorporationHealthcareNASDAQ$237.8M
CAMRFCamurus AB (publ)HealthcareOTC$3.5B
CANFCan-Fite BioPharma Ltd.HealthcareAMEX$1.9M
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Aligos Therapeutics, Inc., and how their positions are changing. At a $7.6M market value, institutional positions materially move Aligos Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Aligos Therapeutics, Inc. executives and directors. Shares of Aligos Therapeutics, Inc. have traded between $3.76 and $46.80 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Aligos Therapeutics, Inc.. Coverage tracks Aligos Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Aligos Therapeutics, Inc.

ALGS AnalysisWeak
Past
1
Growth
1
Health
3
Profit
1
Value
1